Nektar Therapeutics | Ownership
Companies that own Nektar Therapeutics
Fidelity Management & Research Co.
24,854,035
14.41%
1,524,284
0.17%
06/30/2018
PRIMECAP Management Co.
20,902,922
12.12%
-158,973
0.94%
06/30/2018
The Vanguard Group, Inc.
18,020,538
10.45%
1,193,490
0.04%
06/30/2018
OppenheimerFunds, Inc.
11,560,779
6.7%
845,257
0.45%
06/30/2018
BlackRock Fund Advisors
9,716,962
5.63%
-2,693,936
0.03%
06/30/2018
Wellington Management Co. LLP
6,819,244
3.95%
3,344,591
0.09%
06/30/2018
SSgA Funds Management, Inc.
6,003,908
3.48%
-322,695
0.03%
06/30/2018
Henderson Global Investors Ltd.
4,895,968
2.84%
-386,843
0.14%
06/30/2018
Norges Bank Investment Management
2,424,788
1.41%
-148,490
0.02%
12/31/2017
Camber Capital Management LLC
2,000,000
1.15%
500,000
5.4%
06/30/2018
| Address |
455 Mission Bay Boulevard South
San Francisco California 94158
United States
|
|
Employees
|
- |
| Website |
http://www.nektar.com |
| Updated |
07/08/2019 |
| Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA. |
